Nycomed sells remaining Diatide shares
Nycomed Amersham this month completed the divestiture of its remaining holdings in Londonderry, NH-based radiopharmaceutical firm Diatide. On June 16, Nycomed finalized the sale of a total of 1.5 million shares of Diatide common stock to a group
Nycomed Amersham this month completed the divestiture of its remaining holdings in Londonderry, NH-based radiopharmaceutical firm Diatide. On June 16, Nycomed finalized the sale of a total of 1.5 million shares of Diatide common stock to a group of private investors. The terms of the sale were not disclosed by either firm.
The two companies will continue their joint marketing efforts for AcuTect, Diatides FDA-approved acute deep vein thrombosis agent, and for NeoTect, its agent for lung cancer imaging, which is pending approval. Diatide has begun an aggressive business development program in an effort to find other marketing partners for products in its R&D pipeline, the company said. The sale of Buckinghamshire, U.K.-based Nycomeds shares brings to a close a partnership begun in 1995, when Nycomed made a $10 million equity investment in Diatide, then known as Diatech (SCAN 8/30/95).
© 1999 Miller Freeman, Inc.All rights reserved.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
